TVRD — Tvardi Therapeutics Share Price
0.000.00%
Last trade - 00:00- $159.41m
- $121.51m
- $7.14m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 22.34 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -164.65% | ||
| Return on Equity | -270.01% | ||
| Operating Margin | -919.43% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 135.08 | 23.03 | 41.87 | 20.97 | 7.14 | 3.6 | 1.5 | -18.53% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Tvardi Therapeutics, Inc., formerly Cara Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting (STAT3) to treat fibrosis-driven diseases with significant unmet need. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. Its product candidate, TTI-101, is in Phase 2 clinical development for the treatment of fibrosis-driven diseases, with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is an oral, small-molecule, which is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
Directors
- Christopher Posner PRE (52)
- Thomas Reilly CFO (49)
- Frederique Menzaghi SVP (54)
- Scott Terrillion CCO (58)
- Joana Goncalves OTH (47)
- Martin Vogelbaum LED (58)
- Harrison Bains IND (77)
- Jeffrey Ives IND (70)
- Susan Shiff IND (59)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 2nd, 2004
- Public Since
- January 31st, 2014
- No. of Shareholders
- 26
- No. of Employees
- 10
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 9,355,542
- Address
- 400 Atlantic Street, Suite 500, STAMFORD, 06901
- Web
- https://www.caratherapeutics.com/
- Phone
- +1 2034063700
- Auditors
- Ernst & Young LLP
Upcoming Events for TVRD
Cara Therapeutics Inc Annual Shareholders Meeting
Q2 2025 Cara Therapeutics Inc Earnings Release
Similar to TVRD
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Tvardi Therapeutics share price?
As of Today at 23:49 UTC, shares in Tvardi Therapeutics are trading at $17.04. This share price information is delayed by 15 minutes.
How has the Tvardi Therapeutics share price performed this year?
Shares in Tvardi Therapeutics last closed at $17.04 and the price had moved by -35.33% over the past 365 days. In terms of relative price strength the Tvardi Therapeutics share price has underperformed the S&P500 Index by -39.19% over the past year.
What are the analyst and broker recommendations for Tvardi Therapeutics?
The overall consensus recommendation for Tvardi Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Tvardi Therapeutics dividend yield?
Tvardi Therapeutics does not currently pay a dividend.
Does Tvardi Therapeutics pay a dividend?
Tvardi Therapeutics does not currently pay a dividend.
When does Tvardi Therapeutics next pay dividends?
Tvardi Therapeutics does not currently pay a dividend.
How do I buy Tvardi Therapeutics shares?
To buy shares in Tvardi Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Tvardi Therapeutics?
As of the previous close price of $17.04, shares in Tvardi Therapeutics had a market capitalisation of $159.41m.
Where are Tvardi Therapeutics shares listed?
Here are the trading details for Tvardi Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: TVRD
What kind of share is Tvardi Therapeutics?
Based on an overall assessment of its quality, value and momentum Tvardi Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Tvardi Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Tvardi Therapeutics is $110.16. That is 546.52% above the last closing price of $17.04.
Analysts covering Tvardi Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$10.08 for the next financial year.
Find out moreWhat is the trend in the Tvardi Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Tvardi Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +97.85%.
As of the last closing price of $17.04, shares in Tvardi Therapeutics were trading +34.02% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Tvardi Therapeutics PE Ratio?
The Tvardi Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $17.04.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Tvardi Therapeutics?
Tvardi Therapeutics' management team is headed by:
- Christopher Posner - PRE
- Thomas Reilly - CFO
- Frederique Menzaghi - SVP
- Scott Terrillion - CCO
- Joana Goncalves - OTH
- Martin Vogelbaum - LED
- Harrison Bains - IND
- Jeffrey Ives - IND
- Susan Shiff - IND